Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2024

Open Access 01-12-2024 | Research

Effectiveness of Shugan Jieyu capsules for psychiatric symptoms of epilepsy: a systematic review and meta-analysis

Authors: Sejin Kim, Yunna Kim, Seung-Hun Cho

Published in: BMC Complementary Medicine and Therapies | Issue 1/2024

Login to get access

Abstract

Background

The relationship between epilepsy and depression is bidirectional. One condition exacerbates the other. However, there are no current guidelines for treating depression in epilepsy patients. In some cases, seizures worsen when antidepressants (AD) are prescribed or when they are discontinued due to adverse events. The Shugan Jieyu capsule, composed of Acanthopanax senticosus and Hypericum perforatum, is a widely used herbal medicine for treating depression. This study aimed to explore the effectiveness and safety of Shugan Jieyu capsules (SJC) in relieving depression in patients with epilepsy.

Methods

We searched English, Korean, Japanese, and Chinese databases in October 2023 to collect all relevant randomized clinical trials (RCTs). The primary outcomes were the depression scale scores and seizure frequency. The secondary outcomes were quality of life (QoL) and adverse events.

Results

Nine RCTs were included in this meta-analysis. Compared with AD, SJC showed significant differences in the improvement of depression (SMD: 3.82, 95% CI: 3.25, 4.39) and reduction in seizure frequency (MD: 0.39 times/month, 95% CI: 0.28, 0.50). SJC showed more beneficial results than antiepileptic drugs (AED) in terms of antidepressant effects (SMD: 1.10, 95% CI: 0.69, 1.51) and QoL (MD: 11.75, 95% CI: 10.55, 12.95). When patients were prescribed AED, the additional administration of SJC improved depression symptoms (SMD: 0.96, 95% CI: 0.28, 1.63). The SJC treatment group had a lower incidence of side effects than the control group. However, the difference was not statistically significant.

Conclusions

Our results suggest that SJC may be effective in treating depression in patients with epilepsy. Additionally, SJC has the potential to help reduce seizure frequency in epilepsy patients with depression.
Appendix
Available only for authorised users
Literature
1.
Michaelis R, Tang V, Nevitt SJ, Wagner JL, Modi AC, LaFrance WC Jr et al. Psychological treatments for people with epilepsy. Cochrane Database of Systematic Reviews. 2020(8).
2.
Sridharan R. Epidemiology of epilepsy. Current science. 2002:664 – 70.
3.
4.
5.
6.
Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol. 2006;59(1):35–41.PubMedCrossRef
7.
Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, et al. Depression in Epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590–9.PubMedPubMedCentralCrossRef
8.
Kanner AM. Depression and epilepsy: a bidirectional relation? Epilepsia. 2011;52:21 – 7.
9.
10.
Gandy M, Sharpe L, Perry KN. Psychosocial predictors of depression and anxiety in patients with epilepsy: a systematic review. J Affect Disord. 2012;140(3):222–32.PubMedCrossRef
11.
12.
Mehndiratta P, Sajatovic M. Treatments for patients with comorbid epilepsy and depression: a systematic literature review. Epilepsy Behav. 2013;28(1):36–40.PubMedCrossRef
13.
Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia. 1999;40:48–s56.CrossRef
14.
Maguire MJ, Marson AG, Nevitt SJ. Antidepressants for people with epilepsy and depression. Cochrane Database of Systematic Reviews. 2021(4).
15.
Barry JJ, Huynh N, Lembke A. Depression in individuals with epilepsy. Curr Treat Options Neurol. 2000;2(6):571–85.PubMedCrossRef
16.
Yao G, Li J, Wang J, Liu S, Li X, Cao X, et al. Improved resting-state functional dynamics in post-stroke depressive patients after shugan jieyu capsule treatment. Front NeuroSci. 2020;14:297.PubMedPubMedCentralCrossRef
17.
Shuai M, Min J, Xiaoyan X. Meta-analysis of Shugan Jieyu Capsule combined with Escitalopram in the treatment of depression. J Shandong First Med Unversity Shandong Acad Med Sci. 2021;42(5):390.
18.
Fan M, Guo D, Tian Y, Liu Y, Zhao J. Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: a protocol for systematic review and meta-analysis. Medicine. 2021;100(8).
19.
LI Q, Yao J, WU W, YU X, Wang W, HU Y et al. Efficacy and safety of double doses of SHUGANJIEYU capsules in treating moderate depressive disor-der: a multicenter, random, double-blind, and parallel-controlled trial. Chin J Nerv Mental Dis. 2016:580–5.
20.
Ng QX, Venkatanarayanan N, Ho CYX. Clinical use of Hypericum perforatum (St John’s wort) in depression: a meta-analysis. J Affect Disord. 2017;210:211–21.PubMedCrossRef
21.
Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database of Systematic Reviews. 2008(4).
22.
Ernst E, Rand J, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John’s wort (Hypericum perforatum L). Eur J Clin Pharmacol. 1998;54(8):589–94.PubMedCrossRef
23.
Rezaei A, Rezaei-Dorostkar K, Ahmadizadeh C, Jafari B. A comparative study of sedative and anxiolytic effects of the Hypericum perforatumin and diazepam on rats. Zahedan J Res Med Sci. 2012;13(8).
24.
Hosseinzadeh H, Karimi G-R, Rakhshanizadeh M. Anticonvulsant effect of Hypericum perforatum: role of nitric oxide. J Ethnopharmacol. 2005;98(1–2):207–8.PubMedCrossRef
25.
Ivetic V, Popovic M, Mimica-Dukic N, Barak O, Pilija V. St. John’s wort (Hypericum perforatum L.) and kindling epilepsy in rabbit. Phytomedicine. 2002;9(6):496–9.PubMedCrossRef
26.
Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.
27.
Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148–57.PubMedPubMedCentralCrossRef
28.
29.
Liang Y, Yulan H, Bin H, Baoming H, Suping L, poplar, et al. A comparative study on shugan-jieyu capsule and sertraline in the treatment of epilepsy patients combined with mild to moderate depression practical. Hosp Clin J. 2015;12(04):18–20.
30.
Yulan H, Liang Y, Yi H. Effects of Shugan-Jieyu Capsule on mild to Moderate Depression in adult patients with epilepsy. J Chengdu Med Coll. 2015;10(01):66–9.
31.
Xiaoling Z. Effects of Shugan Jieyu capsules on patients with epilepsy and depressive disorder. China Minkang Medicine. 2020;32(20):18–9.
32.
Jiaping X, Zhiru Z, Xiongfei Z, Ruijuan Z. Therapeutic effect of Shugan Jieyu capsule in the treatment of epilepsy complicated with depression. Int J Psychiatry. 2015;42(06):93–5.
33.
Xingmei F, Chunxia L. Analysis of the effect of comprehensive nursing intervention on Shuganjieyu capsule in the treatment of patients with post-epilepsy depression and its optimization and improvement. Disease Surveillance and Control. 2017;11(12):1031–2.
34.
Hongshan P, Cuiying M, Jiayi H. Shuganjieyu Capsule in the treatment of depressive symptoms in patients with Epilepsy: evaluation of clinical efficacy and safety. Chin folk Med. 2016;25(21):64–6.
35.
Chenqi Z, Meiling H, Hongbin S. The efficacy,safety and quality of life of tandospirone and shuganjieyu capsule in the treatment of comorbid anxiety and depression of epilepsy. Practical Hosp Clin J. 2020;17(03):12–5.
36.
Xiaorong W, Xiaolan L, Ya C, Qionggui Z. Analysis of the effect of comprehensive nursing intervention on Shuganjieyu capsule in the treatment of patients with post-epilepsy depression and its optimization and improvement. World Clin Med. 2016;37(04):258–60.
37.
Huan S, Bo L. The efficacy of tandospirone citrate combined with Shugan Jieyu capsule in the treatment of anxiety and depression comorbid with epilepsy. Ration Clin use Drugs. 2023;16(06):57–60.
38.
Hong-bin ZC-qHM-lS. The efficacy, safety and quality of life of tandospirone and shuganjieyu capsule in the treatment of comorbid anxiety and depression of epilepsy. Practical Hosp Clin J. 2020;17(3):12–5.
39.
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343.
40.
41.
Boylan L, Flint L, Labovitz D, Jackson S, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology. 2004;62(2):258–61.PubMedCrossRef
42.
Kondziella D, Asztely F. Don’t be afraid to treat depression in patients with epilepsy! Acta Neurol Scand. 2009;119(2):75–80.PubMedCrossRef
43.
Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63(11):1217–23.PubMedPubMedCentralCrossRef
44.
Hathaway EE, Walkup JT, Strawn JR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: how long is long enough? Curr Probl Pediatr Adolesc Health Care. 2018;48(2):31–9.PubMedPubMedCentralCrossRef
45.
Lam RW, Annemans L. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Rev PharmacoEcon Outcomes Res. 2007;7(6):559–76.PubMedCrossRef
46.
Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457–89.PubMedCrossRef
47.
48.
Zhang M, Bai X. Shugan Jieyu Capsule in Post-stroke Depression Treatment: from molecules to systems. Front Pharmacol. 2022:61.
49.
Jin L, Wu F, Li X, Li H, Du C, Jiang Q, et al. Anti-depressant effects of Aqueous Extract from Acanthopanax senticosus in mice. Phytother Res. 2013;27(12):1829–33.PubMedCrossRef
50.
Bian X, Liu X, Liu J, Zhao Y, Li H, Cai E, et al. Study on antidepressant activity of chiisanoside in mice. Int Immunopharmacol. 2018;57:33–42.PubMedCrossRef
51.
Butterweck V, Winterhoff H, Herkenham M. St John’s wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry. 2001;6(5):547–64.PubMedCrossRef
52.
Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. Epilepsy Behav. 2001;2(6):524–32.PubMedCrossRef
53.
Zhang S-n. Neuroprotection or neurotoxicity? New insights into the effects of Acanthopanax senticosus harms on nervous system through cerebral metabolomics analysis. J Ethnopharmacol. 2014;156:290–300.PubMedCrossRef
54.
Elkommos S, Mula M. A systematic review of neuroimaging studies of depression in adults with epilepsy. Epilepsy Behav. 2021;115:107695.PubMedCrossRef
55.
Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ. 2012;184(3):E191–E6.PubMedPubMedCentralCrossRef
56.
Ma S, Yang J, Yang BX, Kang L, Wang P, Zhang N et al. The Patient Health Questionnaire-9 versus the Hamilton Rating Scale for Depression in assessing major depressive disorder. Front Psychiatry. 2021:1974.
57.
Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two shorter forms of the CES-D depression symptoms index. J Aging Health. 1993;5(2):179–93.PubMedCrossRef
58.
Xia N-g, Ding S-q, Lin J-h, Dong F-r, Du Y-r, Wang X-s, et al. Comparison of the performance of two depression rating scales in patients with epilepsy in southern China. Epilepsy Behav. 2020;106:107025.PubMedCrossRef
Metadata
Title
Effectiveness of Shugan Jieyu capsules for psychiatric symptoms of epilepsy: a systematic review and meta-analysis
Authors
Sejin Kim
Yunna Kim
Seung-Hun Cho
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2024
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-024-04361-0

Other articles of this Issue 1/2024

BMC Complementary Medicine and Therapies 1/2024 Go to the issue

Research

Baicalin enhances proliferation and reduces inflammatory-oxidative stress effect in H2O2-induced granulosa cells apoptosis via USP48 protein regulation

Research

The ameliorative effects of curcumin nanomicelle on testicular damage in the mouse model of multiple sclerosis

Research

PRECIS-2 analysis of pragmatic acupuncture trials: a systematic review

Research

Effects of hand-press pellet on pain and daily life of elders with chronic lower back pain: randomized controlled trial

Research

Effects of Satureja Khuzestanica supplementation on glycemic indices and lipid profile in type 2 diabetes patients: a randomized controlled clinical-trial

Research

Astragalus polysaccharides augment BMSC homing via SDF-1/CXCR4 modulation: a novel approach to counteract peritoneal mesenchymal transformation and fibrosis